Verrica Pharmaceuticals Inc. (VRCA)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-08 · Source: TEK2day Finance
Key Metrics
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 12.7M | 14.3M | 5.1M | 5.0M |
| Gross Profit | 12.2M | 13.2M | 3.7M | 4.1M |
| Operating Income | 1.5M | 1.6M | -6.9M | -9.7M |
| Net Income | 204K | -274K | -8.1M | -9.7M |
| Diluted EPS | $0.02 | $-0.03 | $-0.57 | $-0.45 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 9.0M | 5.1M | 7.6M | 35.6M |
| Gross Profit | 8.3M | 4.4M | 4.8M | 32.1M |
| Operating Income | -21.3M | -63.2M | -65.8M | -11.9M |
| Net Income | -24.5M | -67.0M | -76.6M | -17.9M |
| Diluted EPS | $-7.20 | $-14.80 | $-14.80 | $-1.68 |